OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Woyach on When to Initiate Subsequent Therapy in Patients With CLL

September 23rd 2025

Jennifer A. Woyach, MD, discusses when to initiate subsequent therapy in patients with CLL.

Dr Nadler on the Inherent Complexity of Diagnosing Sarcomas

September 23rd 2025

Eric Nadler, MD, MPP, discusses the inherent complexity of diagnosing sarcomas.

Dr Jerkeman on Symptom Identification for Earlier MCL Diagnosis

September 23rd 2025

Mats Jerkeman, MD, discusses essential symptoms of MCL warranting referral for earlier diagnosis.

Dr Chase on the Importance of Endometrial Cancer Awareness Month

September 23rd 2025

Dana M. Chase, MD, expands on the importance of endometrial cancer awareness month, which is observed annually in September.

Dr Dean on the Role for Pirtobrutinib in Second-Line CLL

September 23rd 2025

Asad Dean, MD, discusses the role of pirtobrutinib in second-line CLL.

Dr Slomovitz on the Importance of Education on Disease Management and Prevention During Gynecologic Cancer Awareness Month

September 23rd 2025

Brian Slomovitz, MD, discusses the importance of education, prevention, and research in the context of gynecologic cancer awareness month.

Dr Tolaney on the Potential Role for Sac-TMT With/Without Pembrolizumab in HR+, HER2– Breast Cancer

September 22nd 2025

Sara M. Tolaney, MD, MPH, discusses the potential role of Sac-TMT with/without pembrolizumab in HR+, HER2– breast cancer.

Dr Leleu on QOL Outcomes With SC Isatuximab Via On-Body Delivery in R/R Myeloma

September 20th 2025

Xavier Leleu, MD, PhD, discusses the role of subcutaneous isatuximab delivered via an on-body delivery system in patients with relapsed/refractory multiple myeloma.

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma

September 20th 2025

Larry Anderson, MD, PhD, discusses updated efficacy and safety findings of subcutaneous daratumumab plus lenalidomide in newly diagnosed multiple myeloma following autologous stem cell transplant.

Dr Farolfi on a Real-World Study of Bevacizumab Plus SOC Therapy in Cervical Cancer

September 19th 2025

Alberto Farolfi, MD, PhD, discusses bevacizumab plus SOC in advanced cervical cancer and no contraindications for antiangiogenic agents.

Dr Gill on a Survey of Patient Experiences and Involvement in Decision-Making in CRC

September 19th 2025

Sharlene Gill, BScPharm, MD, MPH, MBA, FRCPC, discusses patient experiences and involvement in decision-making in CRC.

Dr Nadeem on Efficacy and Safety of Arlo-Cel for R/R Myeloma

September 19th 2025

Omar Nadeem, MD, discusses updated data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr Rodriguez-Otero on Data for Linvoseltamab in High-Risk Smoldering Myeloma

September 19th 2025

Paula Rodriguez-Otero, MD, discusses safety and efficacy findings with linvoseltamab, a bispecific antibody targeting BCMA, in patients with high-risk smoldering multiple myeloma.

Dr Durm on Perioperative Treatment Strategies in Early-Stage NSCLC

September 18th 2025

Greg Durm, MD, discusses factors that influence his decision to utilize perioperative treatment in patients with early-stage NSCLC.

Dr Weinberg on the Rationale for Combining BXCL701 With Pembrolizumab in mPDAC

September 18th 2025

Benjamin A. Weinberg, MD, discusses the rationale for examining BXCL701 plus pembrolizumab in mPDAC.

Dr Tagawa on Factors for Lutetium Lu 177 Vipivotide Tetraxetan Use Before Docetaxel in mCRPC

September 18th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, details factors to consider when to use or defer docetaxel after lutetium Lu 177 vipivotide tetraxetan in mCRPC.

Dr Bekaii-Saab on Evolving Sequencing Approaches in CRC

September 18th 2025

Tanios S. Bekaii-Saab, MD, discusses sequencing decisions according to molecular subgroups in colorectal cancer.

Dr Randall on Advancing Prosthetic Embodiment in Sarcoma Amputation

September 18th 2025

R. Lor Randall, MD, FACS, discusses future research directions for advancing prosthetic embodiment for patients with sarcoma undergoing amputation.

Dr Lorusso on the Rationale for Investigating Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

September 18th 2025

Domenica Lorusso, MD, PhD, details the rationale for the ROSELLA trial, evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Dr San Miguel on the Association Between MRD-Negative CR and PFS/Safety in Newly Diagnosed Myeloma

September 18th 2025

Jesús San Miguel, MD, PhD, discusses patient-reported outcomes and safety for patients with newly diagnosed multiple myeloma who achieved MRD negativity and a CR or better.